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Synthetic drugs present a unique challenge to the international drug control aim to preserve the 
health of the global community. Unlike the production of plant-derived drugs such as cocaine and 
heroin, which is geographically constrained, synthetic drug manufacture can occur anywhere 
depending on human creativity and a few key chemicals.  This versatility makes the manufacture 
of synthetic drugs extremely mobile and any country can be a potential source. Yet this is not a 
totally new phenomenon. For over a century, international drug control has had to contend with 
waves of emergence of synthetic drugs: derivatives of morphine in the 1920s, fentanyl analogues 
in the 1980s and amphetamine-type stimulants in the 1990s. The 2010s marked a defining period 
for synthetic drugs with the unprecedented emergence of hundreds of substances which mimic 
the effects of drugs hazardous to human health and therefore under international control. Known 
as ‘new psychoactive substances’ 
(NPS), by December 2020 over 1,000 
of these had been reported in 120 
countries and territories worldwide. 
For unprepared societies, the effects 
of these cyclical surges in synthetic 
drugs have had severe consequences, 
but none has been as distressing as 
the ongoing synthetic opioids crisis 
affecting mainly North America with 
fentanyl and its analogues, and parts 
of Africa, Asia, and the Middle East with tramadol. 
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 The dynamic nature of synthetic drug 
markets has by necessity required 
equally adaptable solutions and 
continuous refinements of strategies.  
The establishment of the Global 
SMART Programme in 2009 as a 
strategic response to the 
amphetamine-type stimulants 
problem identified in the 2009 
Political Declaration and Plan of 
Action; the development of the first 
global forensic Early Warning Advisory 
on New Psychoactive Substances to operationalize the 2016 UN General Assembly Special Session 
ideal of prioritizing the most harmful, persistent and prevalent substances for international action; 
and the establishment of the UNODC Opioid Strategy in 2018 to support countries in addressing 
the synthetic opioids crisis are all clear examples of the nimbleness with which UNODC has 
responded to the ever-changing and complex synthetic drugs market.     
 
Launched on World Drug 
Day in June 2018, the five-
pillar UNODC Opioid 
Strategy integrates through 
strong inter-agency 
cooperation the unique 
expertise housed within the 
Office with complementary 
specialized knowledge 
across the United Nations 
system. Its operational 
theme of Predict, Protect 
and Prevent leverages a 
robust scientific culture to generate the evidence-base for multilateral decision-making, such as 
the international scheduling of substances, through use of the best available scientific data and 
timely early warning analyses1. Several science-driven multilateral actions over the past few years 
related to some of the most harmful substances ever known to humankind, including several 
fentanyl-analogues, illustrate some of the many successes of the Strategy. Within the framework 
of the Opioid Strategy, UNODC continues to deploy its vast law-enforcement programming assets 
to offer a coordinated response to air, land and sea container and parcel trafficking in priority 







1 Global SMART Programme, the Global Forensic and Scientific Programme 
2 UNODC/WCO Container Control Program, AirCop, the Regional Office for Southeast Asia and the Pacific-Precursors Programme, the Global 
Programme on Cybercrime, Global Programme on Anti-Money-Laundering, CrimJust programme 
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In addition, comprehensive support for 
evidence-based drug demand reduction, 
prevention, treatment and care 
continues to be provided.  A lasting 
legacy beyond the ongoing crisis will be 
the worldwide use and accessibility of 
the United Nations Toolkit on Synthetic 
Drugs – a one-stop shop of cross-cutting 
resources from the UN family for 
addressing both the supply and demand 
elements of the synthetic drug problem. 
 
The Global Synthetic Drug Problem 
 
As illustrated in the World Drug Report, the synthetic drug problem continues to evolve. A few 
examples of emerging challenges include record amounts of methamphetamine being 
manufactured in South-East Asia, despite movement restrictions caused by the COVID-19 
pandemic; geographical shifts in methamphetamine manufacture, for instance in Afghanistan; and 
the increasing emergence of opioid, sedative and stimulant-type new psychoactive substances. 
Such challenges require a recalibration and refinement of current strategies to match a dynamic 
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Several aspects of the global synthetic drug problem affect women in particular. For instance, the 
World Drug Report 2020 reports a higher prevalence of the non-medical use of weight loss pills 
among women compared to men, with pharmaceutical stimulants such as sibutramine 
hydrochloride monohydrate (sold under the brand names Aderan and Ipomex) and phentermine 
(sold under the brand names Duromine and Suprenza), along with methylphenidate and 
amphetamine, being the most commonly misused substances. Similarly, the World Drug Report 
2018 identifies the prevalence of the non-medical use of opioids and tranquillizers among women 
to be at a comparable or higher level to that of men.  
 
Furthermore, women who use drugs, including synthetic drugs, are at a higher risk of infectious 
diseases than men, making up one third of drug users worldwide and accounting for one fifth of 
the estimated global number of people who inject drugs (PWID). Women are more vulnerable than 
men to HIV, hepatitis C and other blood-borne infections and many studies have reported female 
gender as an independent predictor of HIV and/or hepatitis C among PWID, particularly among 
young women and those who have recently initiated drug injection. Women who use drugs also 
face specific challenges including a lack of availability of necessary gender-specific health and drug 
treatment services, barriers to accessing existing services, social stigma and the fear of possible 




While research on issues related to women who use synthetic drugs has improved in recent years, 
data in this area remains scarce and there is a clear need to improve the quality and availability of 
gender disaggregated information.   
 
From Latin America to the Middle East, funding for armed violence has in certain instances long 
been linked to the illicit drug trade. The manufacture of synthetic drugs does not require control 
over large agricultural areas and the local population to grow drug-related crops. Clandestine 
laboratories used to manufacture synthetic drugs are comparatively small in size and the chemicals 
needed can be bought under the guise of licit business. This makes synthetic drugs a particularly 
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Learning from the past – what has worked 
 
The international community’s experiences in responding to previous synthetic drug crises as 
described above, including the most recent opioid crisis which still affects parts of the world, have 
provided some valuable lessons learned with regard to successful approaches: 
 
• A science-informed multilateral process provides the evidence and knowledge on which to 
build effective and targeted policy directions and operational activities. 
• An agile response needs to be based on a strong culture of monitoring, evaluating and 
understanding constantly evolving synthetic drugs markets and their complexity. 
• Early warning provides a predictive model for emerging threats and increases the 
preparedness of Member States to formulate effective responses. 
• An integrated Office-wide approach, coupled with strong inter-agency cooperation, 
leveraging the expertise and in-field presence of flagship UNODC programmes and sister 
agencies from across the UN system, is an efficient and cost-effective way of achieving a 
critical mass for delivery.  
• The availability and accessibility of practical cross-cutting resources and tools from across 
the UN system through a one-stop shop, e.g. the UN Toolkit on Synthetic Drugs, increases 
the comprehensiveness of countries’ responses3. 
 
UNODC Synthetic Drug Strategy 
 
The UNODC Strategy 2021-2025 thematic focus on the world drug problem identifies seven key 






3  The UN Toolkit on Synthetic Drugs features resources and tools from a growing number of UN agencies including 
INCB, UNODC, WHO, UPU, WCO and ICAO and is accessed by experts and agencies in over 170 countries. 
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Aligned with and to advance the implementation of the UNODC Strategy 2021-2025, the 
Synthetic Drug Strategy is built on four synergetic and complementary spheres of action. These 
constitute a framework to guide international, regional and national action to support countries 
to effectively address the growing synthetic drug problem as it manifests around the world with 
particular attention to protecting and empowering vulnerable populations, including children, 
youth, women and people in contact with the criminal justice system and in humanitarian 
settings. 
 





Sphere 1: Multilateralism and international cooperation  
 
• Support scientifically informed multilateral deliberations through the 
Commission on Narcotic Drugs and international cooperation activities to 
identify emerging synthetic drug challenges and mobilize relevant 
institutions to identify system-wide synergies and options for response. 
• Support UNODC’s normative work as it relates to the international scheduling framework 
and strengthen the process of incorporation of decisions into national legislative 
frameworks to support the implementation of scheduling decisions. 
• Support the prioritization of the most harmful, prevalent and persistent substances for 
international action.  
• Ensure system-wide coherence on the science of synthetic drugs through proactive 
consultations with the treaty bodies (Commission on Narcotic Drugs (CND), World Health 
Organization (WHO), and International Narcotics Control Board (INCB)) and other UN 
agencies, regional organizations, academia, the scientific community and the chemical and 
pharmaceutical industries. 
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Sphere 2: Early warning on emerging synthetic drug threats - Preventing crises before 
they happen 
 
• Enable early detection and prompt responses by national institutions to emerging 
threats related to synthetic drugs and their precursor chemicals. 
• Promote and improve the collection and analysis of reliable and comparable data to 
strengthen evidence-based responses, with particular focus on at-risk populations 
including women and youth.  
• Strengthen the capacity of forensic drug testing and toxicology laboratories worldwide to 
identify synthetic drugs, including NPS, and increase the use of such knowledge in strategic 
interventions and policy decisions. 
• Build the capacity of national institutions to contribute to and strengthen forensic early 
warning systems worldwide. 
• Support the development of a global campaign aimed at raising awareness of the threats 
posed by synthetic drugs, including the dissemination of early warning messages via the 
UNODC Forensic Early Warning Advisory. 
• Enter into strategic partnerships with forensic and scientific associations and academic 
institutions to facilitate access to scientific best practice and knowledge to respond to 
emerging synthetic drug threats. 
• Increase the understanding of toxic adulterants and the use of pharmaceuticals (and 
counterfeit medicines) with known effects in the production of synthetic drugs.  
 
 
Sphere 3: Promote science-informed health responses - “Science for health” 
 
• Promote non-stigmatizing attitudes with a focus on gender and marginalized 
communities to ensure the availability, access and delivery of health, care and social 
services for people who use drugs.  
• Promote awareness-raising, education and training as part of a comprehensive approach 
to ensuring the access and availability of internationally controlled substances for medical 
and scientific purposes and improving their rational use, while preventing their diversion 
and abuse. 
• Promote and facilitate access to comprehensive, scientific evidence-based, affordable 
quality drug prevention, treatment, care, sustained recovery and related support services, 
with particular consideration for the needs of women, youth and vulnerable communities, 
including for people impacted by social marginalization. 
• Enhance international scientific collaboration across the UN system to promote effective 
interventions related to synthetic drugs, including opioid overdoses and the management 
and treatment of synthetic drug use disorders. 
• Enhance the guidance available for the management of infants born with neonatal 
abstinence syndrome resulting from prenatal exposure to synthetic drugs, in particular 
synthetic opioids, to ensure the best possible outcomes and that no infant is left behind.  
• Promote measures to prevent the transmission of HIV as well as to prevent and treat viral 
hepatitis C attributable to synthetic drug use. 
• Improve the participatory role of civil society in addressing the synthetic drug problem, 
including the community of people who use drugs. 
• Promote the involvement of youth in drug prevention efforts. 
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 Sphere 4: Strengthen counternarcotic capacity and support international operations 
to disrupt trafficking in synthetic drugs 
 
• Leverage innovation and technology to make science accessible to counternarcotic 
and law enforcement entities to better inform and facilitate counternarcotic 
operations and interdiction decisions, including drug identification, safe handling and the 
disposal of synthetic drugs and their precursors. 
• Promote private-public partnerships to support counternarcotic capacity to disrupt and 
interdict trafficking in synthetic drugs, including the disposal of toxic chemicals and 
precursors used in the manufacture of synthetic drugs.  
• Prevent and counter the diversion and trafficking of precursors and pre-precursors used in 
the illicit manufacture of synthetic drugs. 
• Enhance the capacity of online investigative units to identify, intercept, interdict and 
disrupt online trafficking in synthetic drugs as well as to seize cryptocurrencies used to 
transact such trafficking.  
• Build the capacity of frontline law enforcement and forensic personnel to disrupt the supply 
chain and expand law enforcement activities targeting both traditional and online 
trafficking.  
• Enhance the access of law enforcement entities and criminal justice systems to quality and 
reliable in-country forensic science services operated at internationally accepted 
standards. 
• Encourage the adoption of national chemical disposal plans that are informed and guided 
by the science of safe handling and disposal. 
